Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
(World News Science)

Downloads 20200802_Immunic_IMU-838_Top-line_MS_data_and_Q2_2020_Earnings File size:315 KB - Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis - - Statistically Significant Reduction of 62% and 70% in Combined Unique Active Magnetic Resonance Imaging Lesions in 45mg and 30mg Patient Cohorts, As Compared to Placebo - - Data Supports Previously Observed Favorable Safety Profile of IMU-838 in Relapsing-Remitting Multiple Sclerosis Patient Population - - Company Also Reports Second Quarter 2020 Financial Results With $48.6 Million in Cash and Cash Equivalents - - Conference Call and Webcast...